“In regards to the support of the pharmaceutical and biotechnology fields, Korean drugs should be preferentially treated”
At a meeting with the National Health Insurance Service and Health Insurance Review & Assessment Service journalists on the 26th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA) Chairman Hee-Mok Won emphasized importance of the ‘predictable and rational health insurance benef...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
